ILMN

ILMN

USD

Illumina Inc. Common Stock

$77.880-0.120 (-0.154%)

实时价格

Healthcare
Diagnostics & Research
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$78.000

最高价

$79.220

最低价

$77.050

成交量

0.17M

公司基本面

市值

12.3B

所属行业

Diagnostics & Research

国家/地区

United States

交易统计

平均成交量

2.71M

交易所

NMS

货币

USD

52周价格范围

最低价 $68.7当前价 $77.880最高价 $156.66

AI分析报告

最后更新: 2025年4月30日
由AI生成数据来源: Yahoo Finance, Bloomberg, SEC

ILMN: Illumina Inc. Common Stock - What's Happening and What to Watch

Stock Symbol: ILMN Generate Date: 2025-04-30 11:10:43

Alright, let's break down what's been going on with Illumina (ILMN) lately and try to figure out what it might mean. Think of this as a quick chat about the stock, cutting through the noise.

The Latest Buzz: News and Analyst Takes

Looking at the recent news, it's a bit of a mixed bag, but with a noticeable lean towards caution from the pros.

  • Several analysts have recently lowered their price targets for Illumina. Canaccord Genuity dropped theirs from $115 to $92, and Barclays went even lower, from $100 to $77. RBC Capital also trimmed their target, moving from $128 to $112, though they still keep an "Outperform" rating, which is more positive than the "Hold" or "Underweight" ratings from the others.
  • So, the general feeling from these analyst moves? They seem to think the stock isn't worth quite as much as they previously did. That's usually not a great sign for immediate price action.
  • On a more positive note, there's news about Illumina partnering with Tempus AI to work on "genomic AI innovation." This ties into a broader trend mentioned in another piece about the global AI diagnostics market growing significantly. This kind of partnership shows the company is trying to stay relevant and tap into hot areas like AI in healthcare.
  • Something important coming up is the company's First Quarter 2025 financial results, set for May 8th. Earnings reports are always a big deal and can cause the stock price to jump or drop significantly depending on the numbers and the company's outlook.

Putting the news together, you've got analysts getting a bit less optimistic on one hand, and the company pushing into exciting AI areas on the other. The upcoming earnings report is a major event that will likely shape the near future.

Checking the Price Chart: A Rocky Ride

Now, let's look at what the stock price itself has been doing. If you glance at the last few months of data, it's been a pretty tough stretch.

  • Back in late January, the stock was trading up around $130-$135. Fast forward to the end of April, and it's hovering around the mid-$70s. That's a significant drop over this period.
  • The price action hasn't been smooth sailing either. There were some sharp drops, particularly in early February and again in early March and April.
  • More recently, in April, the price seems to have found a bit of a floor, trading mostly between the low $70s and high $70s. It looks like it's been trying to stabilize after that big fall. The last recorded price on April 29th was $77.10.

What about the AI's take on the very near future? The prediction model suggests a tiny dip today (-0.08%), a small bump tomorrow (+0.13%), and then a more noticeable gain the day after (+1.71%). This hints that the AI sees some potential for a move up just beyond the immediate couple of days.

What Does This All Suggest? Outlook and Potential Moves

Based on the news, the price history, and the AI's short-term view, here's a way to think about it:

  • The Apparent Near-Term Leaning: Right now, the situation seems to lean towards a 'Hold' or 'Wait-and-See' approach, especially with the earnings report just around the corner. The analyst downgrades are a yellow flag, even if the AI partnership is a positive long-term signal. The price has stabilized recently, which is good, but it's still way down from earlier levels.
  • Why 'Hold' or 'Wait'? The market is clearly reacting to something that caused those analyst targets to drop. While the AI news is promising, it might not impact the financials immediately. The earnings report on May 8th is the next big catalyst. Waiting to see those results and the company's guidance could provide much clearer direction.
  • Potential Entry Consideration (If you're patient): If the earnings report is surprisingly positive, or if the stock holds firm around these recent levels (say, staying above the low $70s), that could be a point where some investors might consider looking closer. The AI prediction for a move up in a few days might align with a positive post-earnings reaction, but that's speculative. The recommendation data pointed to potential entry points around $76.43-$76.96, which is right where it is now, suggesting some models see this area as interesting if you believe in a bounce.
  • Potential Exit/Stop-Loss Consideration: If you currently own the stock, setting a stop-loss order below a recent low (like the $68.70 52-week low hit recently) could help protect against further significant drops, especially if the earnings report disappoints. For those looking to potentially take profits if it does bounce, the AI's potential target of $106.71 or the higher analyst targets ($92, $112) represent areas where the stock could face resistance, but these are quite a bit above the current price.

A Little More Context on Illumina

Remember, Illumina is a big player in the world of genetic and genomic analysis. They make the machines and materials used to read DNA. Their business serves research labs, hospitals, and biotech companies. The move into AI diagnostics makes sense for them, as analyzing massive amounts of genetic data is exactly where AI can help.

However, the company details also show some challenges: negative revenue growth recently, low return on equity, and relatively high debt. These fundamental points are likely part of why analysts have become more cautious, despite the potential in AI. The stock's P/E ratio around 17.4x is neutral, not screaming cheap or expensive based on current earnings.

So, it's a company with exciting technology potential but facing some current financial headwinds and analyst skepticism. The next earnings report is key.


Disclaimer: This analysis is based on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

相关新闻

PR Newswire

Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development

Illumina, Inc. (NASDAQ: ILMN), and Ovation.io, Inc., an organization dedicated to building best-in-class multiomics datasets, today announced the...

查看更多
Illumina and Ovation.io launching first-of-kind GLP-1 dataset to accelerate new therapy development
Analyst Upgrades

Canaccord Genuity Maintains Hold on Illumina, Lowers Price Target to $92

Canaccord Genuity analyst Kyle Mikson maintains Illumina with a Hold and lowers the price target from $115 to $92.

查看更多
Canaccord Genuity Maintains Hold on Illumina, Lowers Price Target to $92
GlobeNewswire

Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations

PALM BEACH, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Artificial intelligence (AI) is being utilized for disease detection in the global markets. In today's AI-driven world, the use of

查看更多
Global AI Diagnostics Market to Reach $8.54 Billion By 2033 as Industry Sees Increasing R&D and Strategic Collaborations
PR Newswire

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and...

查看更多
Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation
PR Newswire

Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025

Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2025 following the close of market on Thursday, May 8,...

查看更多
Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025
Analyst Upgrades

Barclays Maintains Underweight on Illumina, Lowers Price Target to $77

Barclays analyst Luke Sergott maintains Illumina with a Underweight and lowers the price target from $100 to $77.

AI预测Beta

AI建议

看涨

更新于: 2025年5月3日 09:29

看跌中性看涨

60.1% 置信度

风险与交易

风险等级3/5
中风险
适合于
保守
交易指南

入场点

$77.51

止盈点

$79.44

止损点

$70.09

关键因素

PDI 7.2高于MDI 6.5,且ADX 8.8,表明看涨趋势
当前价格非常接近支撑水平$77.76,表明有强烈的买入机会
交易量是平均值的4.3倍(23,761),表明极强的买入压力
MACD -0.0007低于信号线0.0146,表明看跌交叉

保持更新

设置价格提醒,获取AI分析更新和实时市场新闻。